HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone

• Published in: Cancer research (Chicago, Ill.) Vol. 77; no. 1; pp. 74 - 85
• Main Authors: Day, Kathleen C., Hiles, Guadalupe Lorenzatti, Kozminsky, Molly, Dawsey, Scott J., Paul, Alyssa, Broses, Luke J., Shah, Rajal, Kunja, Lakshmi P., Hall, Christopher, Palanisamy, Nallasivam, Daignault-Newton, Stephanie, El-Sawy, Layla, Wilson, Steven James, Chou, Andrew, Ignatoski, Kathleen Woods, Keller, Evan, Thomas, Dafydd, Nagrath, Sunitha, Morgan, Todd, Day, Mark L.
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research, Inc 01.01.2017
• Subjects: Animals; Blotting, Western; Bone cancer; Bone Neoplasms - secondary; Bone tumors; Cell Line, Tumor; Disease Progression; Epidermal growth factor receptors; ErbB Receptors - biosynthesis; ErbB-1 protein; ErbB-2 protein; Flow Cytometry; Gene amplification; Heterografts; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Metastases; Metastasis; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness - pathology; Neoplastic Cells, Circulating - pathology; Neoplastic Stem Cells - pathology; NF-κB protein; Prostate cancer; Prostatic Neoplasms - pathology; Receptor, ErbB-2 - biosynthesis; Tissue Array Analysis; Tumor cells; Up-Regulation; Xenografts

Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression of multiple cancer types through complex mechanisms that are still not fully understood. In this study, we report that HER2 expression is elevated in bone metastases of prostate cancer independently of gene amplific...